ALXO
ALX ONCOLOGY HOLDINGS INC
NASDAQ · Healthcare · Biotechnology · US
$1.70
−2.30%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +30.8%
- EBIT
- +32.1%
- EPS
- +48.6%
- Free cash flow
- +32.9%
- Operating cash flow
- +32.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +50.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- +24.8%
- EBIT
- +27.0%
- Net income
- +24.6%
- EPS
- +26.4%
- Free cash flow
- +31.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026